

PREScribed LIST

AUGUST 2025

**Products available as
Pharmaceutical Benefit under the
Health Insurance (Jersey) Law 1967**



Get access now!

Step 1: Download the app
Search the app store for "Eolas Medical"



Step 2: Scan the QR Code
Scan the code after downloading the app to
get access to your Space.



Need help getting access? email support@eolasmedical.com

1. How to use the Prescribed List

- Items are listed by generic name using [dm+d](#) descriptions unless the product is a complex preparation and listed (and reimbursed) by brand name
 - **Open order:** items listed as 'open order', may be prescribed by generic or brand name and the corresponding non-proprietary or proprietary product dispensed that meets the prescription. Reimbursement will be for the brand or generic product prescribed.
 - **Brand name specified:** for items listed as 'Brand', only the specified brand will be reimbursed.
 - **Generic only:** items listed as 'Generic' must be prescribed by generic name and will be reimbursed at the price stated in Part VIII of the current Drug Tariff.

2. Period of supply and repeat prescriptions

See HEALTH INSURANCE (PHARMACEUTICAL BENEFIT) (GENERAL PROVISIONS) (No. 2) (AMENDMENT No. 15) (JERSEY) ORDER 2023

- 2.1 An approved prescribing practitioner, other *than a dentist*, must not give a prescription for the supply of pharmaceutical benefit to a person for a period exceeding 90 days.
- 2.2 An approved prescribing practitioner who is a dentist must not give a prescription for the supply of pharmaceutical benefit to a person for a period exceeding 30 days.
- 2.3 An approved prescribing practitioner must not give more than one prescription for the same pharmaceutical benefit at any one time.
- 2.4 However, an approved prescribing practitioner may give up to 4 prescriptions in respect of the same pharmaceutical benefit at any one time if the prescriptions are for consecutive periods of supply.
- 2.5 An approved prescribing practitioner must not during a period of treatment give a further prescription to a person for the same pharmaceutical benefit unless the practitioner is satisfied that it is necessary or desirable to do so for the purpose of the treatment and –
 - (a) the pharmaceutical benefit is intended for the continuation of the treatment after the expiry of the present period of treatment and the prescription is dated no earlier than 21 days before the end of that period.
 - (b) the prescription is for an increase in dosage; or
 - (c) the prescription is to replace pharmaceutical benefit previously supplied on prescription and destroyed or lost.
- 2.6 An approved supplier must not supply pharmaceutical benefit ordered on a prescription –
 - (a) before the effective date of the prescription; or
 - (b) which does not comply with the requirements of this Article.

3. Pricing of Prescriptions

- The prescriptions are priced according to the Drug Tariff for England and Wales, available at <https://www.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/drug-tariff>.

4. Prescription Charges: Please note that prescription charges are abolished.

5. Instalment dispensing fees

- When a doctor has requested dispensing at stipulated intervals, instalment-dispensing fees may be claimed if the medicine is listed in Part I, II or III of the second schedule to the Misuse of Drugs (Jersey) Law 1978.

6. Submitting of prescriptions for pricing

- Prescriptions should be submitted each month to the Department for Employment, Social Security and Housing at Union Street, St Helier. Normally this is by the third working day (Mon-Fri), but if there is a Bank Holiday in the month (January, April, May, August, and December), then it is the second working day. All prescriptions must be submitted by 2p.m. on the final day to ensure accurate preparation of the payment schedules.
- The prescriptions are then sent to NHS Business Services Authority in Newcastle for processing.

7. Payment of Prescriptions

- On the submission of a month's prescriptions, an estimated payment is made based on the number of items claimed multiplied by the pharmacy's average cost per item from the previous priced month.
- This figure is then adjusted by the amount under/overpaid in the estimate of the previous month; the actual figure being calculated from NHSBSA's pricing of the prescriptions.

8. Remuneration

- There are two elements to the remuneration for dispensing: dispensing fees and discount. A fee is paid for the dispensing of each prescription and sundry dispensing fees e.g. for a controlled drug, for expensive items.

9. Data Processing Notice

- Information about prescriptions written by primary care practitioners is processed by the NHS Business Services Authority (NHSBSA) in line with the Data Protection Act 2018.
- As data Controllers, the Government of Jersey ask NHSBSA to process data so that payment for dispensing pharmacies can be calculated and the Government of Jersey can understand and manage prescribing in the community.
- Information that identifies individual patients is not processed or retained electronically.
- Information identifying the prescriber and dispenser, as well as the medicine, its strength, form, quantity, and cost for reimbursement, is stored securely in the NHS ePACT data system for five years. This data is used to produce anonymised, island wide analysis that can be used to comment on prescribing trends or the cost of medicines and respond to specific queries regarding a particular type of medicine.
- Prescribing data is also accessed and analysed to contribute to the appraisals and revalidation of GPs and other prescribers, as required by the Medical Practitioners (Jersey) Law 1960 and in partnership with the Primary Care Governance Team who have responsibility for the oversight of primary care activity in Jersey.
- For more information on how we use your data please go to our privacy statements on gov.je or request a written copy of the Government of Jersey Privacy Statement by phoning 01534 444444

10. Changes to the Prescribed List

10.1 New products from 1 August 2025

Prednisolone sodium phosphate 0.5% eye drops 0.5ml unit dose preservative free
Carbocisteine 250mg/5ml oral solution sugar free
Tamoxifen 10mg/5ml oral solution sugar free
Fludrocortisone 50mcg tablets
Tacrolimus 750 microgram capsules
Colecalciferol 440unit / Calcium carbonate 1.25g effervescent granules sachets
Colecalciferol 400unit / Calcium carbonate 1.5g effervescent tablets
Mesalazine 1.6g gastro-resistant tablets
Nitrofurantoin 50mg capsules
Nitrofurantoin 100mg capsules
Levetiracetam 1g tablets
Ropinirole 3mg modified-release tablets
Ropinirole 6mg modified-release tablets
Ethinylestradiol 35microgram / Norethisterone 500microgram tablets
Aciclovir 200mg dispersible tablets
Aciclovir 400mg dispersible tablets
Aciclovir 800mg dispersible tablets
Fluorouracil 4% cream

10.2 Other changes

The following products should be prescribed by generic name from 1 October 2025

Amorolfine 5% medicated nail lacquer
Clindamycin 1% aqueous lotion
Clindamycin 2% vaginal cream
Otomize (Dexamethasone 0.1% / Neomycin 0.5% / Acetic acid (glacial) 2%) ear spray
Azelastine 137micrograms/dose / Fluticasone 50micrograms/dose nasal spray
Medroxyprogesterone 5mg tablets
Medroxyprogesterone 10mg tablets
Medroxyprogesterone 100mg tablets
Medroxyprogesterone 200mg tablets
Conjugated oestrogens 300microgram tablets
Conjugated oestrogens 625microgram tablets
Conjugated oestrogens 1.25mg tablets

10.3 Removal of products from 1 January 2026

Salbutamol 500micrograms/1ml solution for injection ampoules
Salbutamol 5mg/5ml solution for infusion ampoules
Insulin isophane biphasic porcine 30/70 100units/ml suspension for injection 10ml vials (Brand: Hypurin Porcine 30/70 Mix)
Insulin isophane biphasic porcine 30/70 100units/ml suspension for injection 3ml cartridge
Exenatide 5micrograms/0.02ml solution for injection 1.2ml pre-filled disposable device
Exenatide 10micrograms/0.04ml solution for injection 2.4ml pre-filled disposable device
Cu-Safe® T300
Mini TT 380® Slimline
Multi-Safe® 375 Short Stem
Cyanocobalamin 1mg/1ml solution for injection ampoules
Aveeno Lotion
Aveeno daily moisturising body cleaning oil
Pneumococcal polysaccharide vaccine solution for injection 0.5ml vials

11. Prescribing of liothyronine following specialist initiation only

- Liothyronine should only be prescribed in exceptional circumstances, following recommendation by a specialist, due to its weak evidence-base and very high cost. Such circumstances include clearly distinguishable specific levothyroxine medication intolerance, including extremely rare cases of levothyroxine induced liver injury, or where there is evidence that a patient cannot effectively metabolise levothyroxine to liothyronine.
- If liothyronine is required, it should be prescribed as **capsules**, which are less expensive than liothyronine tablets.

12. Prescribing of liraglutide – starting and stopping criteria for weight management

- No new patients should be initiated on liraglutide for weight management due to lack of access to discounted price in primary care
- Liraglutide **must be prescribed by brand name** to ensure that the patient receives the product appropriate to the indication for use.

13. Prescribing of semaglutide

- **Semaglutide must be prescribed by brand name** (Ozempic for diabetes/Wegovy for weight loss) to ensure that the patient receives the product appropriate to the indication for use.
- Semaglutide (Wegovy brand) is **not** reimbursed under the Health Insurance Fund (HIF) and can only be prescribed on private prescription

14. Prescribing of tirzepatide

- Prescriptions for tirzepatide will only be reimbursed under the HIF when prescribed **in line with [NICE TA 924](#)** as part of the management of **type 2 diabetes where combination therapy including metformin is ineffective, not tolerated or contraindicated**.
- Eligible prescriptions under the HIF **must include the annotation ‘for treatment of type 2 diabetes’** clearly stated on the form by the prescriber. Prescriptions with the annotation will be dispensed at no cost to the patient and the pharmacy will receive reimbursement.
- For all other indications, tirzepatide should be prescribed on private prescription.
- HIF prescriptions for tirzepatide that are not appropriately annotated will not be reimbursed.
- Prescribing levels will be monitored and audited.
- Recovery of costs will be sought where tirzepatide is supplied outside of this guidance.